Related Experiment Video
Updated: Feb 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or
Vincent Chow1, Peter J Winkle2, Daniel T Mytych1
1Amgen Inc., Thousand Oaks, CA, USA.
Abstract:
ABP 654, a biosimilar to ustekinumab reference product, is available in a prefilled syringe (PFS) for subcutaneous (SC) use. The ABP 654 autoinjector pen (AIP) has recently been developed with an aim to improve the injection experience for patients and caregivers. This study was designed to assess the similarity of pharmacokinetics (PK), safety, and immunogenicity of a 90-mg SC injection of ABP 654 administered via PFS or AIP in healthy volunteers. A total of 156 adults were randomized at a ratio of 1:1. PK bioequivalence was established between the PFS and AIP groups based on the 90% CIs of the geometric mean ratios for the primary PK endpoints of maximum observed serum concentration (Cmax) and area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) being contained within the prespecified margin of 0.8 to 1.25. The frequency, type, and severity of adverse events as well as the incidence of antidrug antibodies were similar between the PFS and AIP groups. Overall, the results support a conclusion of PK bioequivalency as well as comparable safety and immunogenicity of ABP 654 administered via PFS and AIP.
Related Concept Videos
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Products: Biologics, Biosimilars and Interchangeables
Parallel Resonance
Parallel Processing
Random Error

